Literature DB >> 18429047

Reduced half-life of holocarboxylase synthetase from patients with severe multiple carboxylase deficiency.

Lisa M Bailey1, Ruby A Ivanov, Sarawut Jitrapakdee, Callum J Wilson, John C Wallace, Steven W Polyak.   

Abstract

Multiple carboxylase deficiency is a clinical condition caused by defects in the enzymes involved in biotin metabolism, holocarboxylase synthetase (HLCS) or biotinidase. HLCS deficiency is a potentially fatal condition if left untreated, although the majority of patients respond to oral supplementation of 10-20 mg/day of biotin. Patients who display incomplete responsiveness to this therapy have a poor long-term prognosis. Here we investigated cell lines from two such HLCS-deficient patients homozygous for the c.647T>G p.L216R allele. Growth of the patients' fibroblasts was compromised compared with normal fibroblasts. Also the patient cells were not sensitive to biotin-depletion from the media, and growth rates could not be restored by re-administration of biotin. The molecular basis for the HLCS deficiency was further investigated by characterisation of the p.L216R protein. The HLCS mRNA was detected in MCD and normal cell lines. However, protein and enzyme activity could not be detected in the patients' cells. In vitro kinetic analysis revealed that enzyme activity was severely compromised for recombinantly expressed p.L216R and could not be increased by additional biotin. Furthermore, the turn-over rate for the mutant protein was double that of wildtype HLCS. These results help provide a molecular explanation for the incomplete biotin-responsiveness of this p.L216R form of HLCS. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18429047     DOI: 10.1002/humu.20766

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

Review 1.  Antenatal and postnatal radiologic diagnosis of holocarboxylase synthetase deficiency: a systematic review.

Authors:  Sahan P Semasinghe Bandaralage; Soheil Farnaghi; Joel M Dulhunty; Alka Kothari
Journal:  Pediatr Radiol       Date:  2016-01-11

2.  Effects of single-nucleotide polymorphisms in the human holocarboxylase synthetase gene on enzyme catalysis.

Authors:  Shingo Esaki; Sridhar A Malkaram; Janos Zempleni
Journal:  Eur J Hum Genet       Date:  2011-10-26       Impact factor: 4.246

3.  A novel molecular mechanism to explain biotin-unresponsive holocarboxylase synthetase deficiency.

Authors:  Lungisa Mayende; Rachel D Swift; Lisa M Bailey; Tatiana P Soares da Costa; John C Wallace; Grant W Booker; Steven W Polyak
Journal:  J Mol Med (Berl)       Date:  2011-09-06       Impact factor: 4.599

4.  Clinical Presentation and Positive Outcome of Two Siblings with Holocarboxylase Synthetase Deficiency Caused by a Homozygous L216R Mutation.

Authors:  T P Slavin; S J Zaidi; C Neal; B Nishikawa; L H Seaver
Journal:  JIMD Rep       Date:  2013-09-13

5.  Paracentric Inversion of Chromosome 21 Leading to Disruption of the HLCS Gene in a Family with Holocarboxylase Synthetase Deficiency.

Authors:  Shane C Quinonez; Andrea H Seeley; Cindy Lam; Thomas W Glover; Bruce A Barshop; Catherine E Keegan
Journal:  JIMD Rep       Date:  2016-08-13

6.  Clinical, biochemical, and genetic analysis of a Chinese Han pedigree with holocarboxylase synthetase deficiency: a case report.

Authors:  Zhenzhu Zheng; Gaopin Yuan; Minyan Zheng; Yiming Lin; Faming Zheng; Mengyi Jiang; Lin Zhu; Qingliu Fu
Journal:  BMC Med Genet       Date:  2020-07-29       Impact factor: 2.103

7.  Identification and targeted management of a neurodegenerative disorder caused by biallelic mutations in SLC5A6.

Authors:  Nicholas J Smith; Hamish S Scott; Alicia B Byrne; Peer Arts; Steven W Polyak; Jinghua Feng; Andreas W Schreiber; Karin S Kassahn; Christopher N Hahn; Dylan A Mordaunt; Janice M Fletcher; Jillian Lipsett; Drago Bratkovic; Grant W Booker
Journal:  NPJ Genom Med       Date:  2019-11-14       Impact factor: 8.617

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.